We are determined to bring the full power of data to the collective fight against cancer.


Through our research and partnerships, we are helping to shape the real-world evidence industry and advance the field of oncology.
Our collaborations are leading industry to advance the treatment landscape, reimagine the drug development life cycle, and accelerate value-based care models.


Improving Patients’ Experiences and Outcomes with Technology and Real-World Data

Leading the data and digital team at Novartis, Bruno Villetelle believes that real world data should have a real world impact on patient care. He joins the #RealWorldTalk podcast to discuss how technology and data collection are being used at all stages of treatment to improve patients’ experiences and outcomes.

The Lancet Rheumatology Publishes Additional Findings on Tocilizumab, Fueled by Real-World Data

A recent observational study using real world data shows promising results from using tocilizumab in patients with severe COVID-19. According to study co-author Shivam Mathura, “While these results need to be further validated through clinical trials, we are thrilled to provide early insights to those in the field as we continue to fight this pandemic.”

COTA Featured in BioCentury – Real World Data’s Power to Increase Racial Diversity in Clinical Research

COTA’s Chief Medical Officer, Dr. C.K. Wang spoke with BioCentury to help further the conversation around the role of RWD in increasing racial diversity in clinical research.


Our Research

Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

In this retrospective observational cohort study involving 13 hospitals within the Hackensack Meridian Health network (NJ, USA), patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomized controlled trials are awaited.

ESMO IO 2019: Cost of Adverse Events (AEs) With Second-line (2L) Immuno-Oncology Agents (IO) and Chemotherapy (CHEMO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) in the Real World

In collaboration with Bristol-Myers Squibb, COTA investigated the incidence and cost of adverse events among aNSCLC patients treated with 2L immuno-oncology agents as compared to 2L chemotherapy, finding lower cost among patients treated with IO.

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer

COTA was one of six organizations to participate in a collaboration to explore the consistency of real-world endpoints across diverse datasets and the potential validity of RWD to support regulatory and payer decision making.

ASCO 2019: Rates of Genotyping for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair in Metastatic Colon Cancer Patients: Gaps and Implications.

In collaboration with Guardant Health, COTA investigated the molecular testing rates of patients with metastatic colon cancer and found that <25% of our cohort received guideline recommended genotyping.

ASCO 2019: Real-World Characterization of Advanced/Metastatic Non-Small Cell Lung Cancer Patients with Rapid Disease Progression

In collaboration with Eli Lilly, COTA characterized patients with non-small cell lung cancer whose disease progresses within <12 weeks of diagnosis, a notable poor prognosis cohort.

ASH 2019: Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Using COTA RWD, our research showed that newly diagnosed multiple myeloma patients with histories of prostate cancer and those with two or more prior malignancies were more likely to have amp(1q), a poor prognostic marker in MM.

Interested in learning more about how we can transform cancer care together?